HC Wainwright Cuts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $390.00
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price objective decreased by HC Wainwright from $425.00 to $390.00 in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the company. Bank of […]
More Stories
Nexstar Media Group (NASDAQ:NXST) Price Target Cut to $198.00
Nexstar Media Group (NASDAQ:NXST – Get Free Report) had its price target lowered by analysts at Guggenheim from $200.00 to...
Critical Survey: Cybin (CYBN) versus Its Rivals
Cybin (NYSE:CYBN – Get Free Report) is one of 443 publicly-traded companies in the “Biotechnology” industry, but how does it...
Nuvalent (NASDAQ:NUVL) PT Raised to $125.00
Nuvalent (NASDAQ:NUVL – Get Free Report) had its target price hoisted by equities research analysts at JPMorgan Chase & Co....
Baidu, Inc. (NASDAQ:BIDU) Given Consensus Rating of “Moderate Buy” by Brokerages
Baidu, Inc. (NASDAQ:BIDU – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eighteen brokerages that...
NRG Energy, Inc. (NYSE:NRG) Receives Average Recommendation of “Hold” from Brokerages
NRG Energy, Inc. (NYSE:NRG – Get Free Report) has been given an average recommendation of “Hold” by the eight ratings...
NIKE (NYSE:NKE) Price Target Cut to $77.00
NIKE (NYSE:NKE – Free Report) had its target price cut by JPMorgan Chase & Co. from $80.00 to $77.00 in...